Lung Cancer Liquid Biopsy Market Outlook Highlights Strategic Opportunities Across The Industry

The lung cancer liquid biopsy market is set to experience significant expansion in the coming years, driven by advancements in diagnostic technology and increasing demand for personalized oncology approaches. As the healthcare sector evolves, this market is becoming a crucial component in early cancer detection and treatment monitoring. The following sections offer a detailed overview of its size, key players, emerging trends, and segmentation.

Projected Growth Outlook of the Lung Cancer Liquid Biopsy Market
The size of the lung cancer liquid biopsy market is forecasted to grow substantially, reaching $2.42 billion by 2030. This expansion reflects a strong compound annual growth rate (CAGR) of 16.7% during the forecast period. The surge in market value is attributed to rising demand for precision oncology solutions, broader applications of liquid biopsy in clinical settings, increased use of companion diagnostics, and the integration of AI-powered data analytics. Additionally, there is a growing emphasis on early cancer screening programs, which further propels market growth. Prominent trends include the adoption of non-invasive testing methods, a rise in next-generation sequencing (NGS)-based liquid biopsy assays, and a shift towards personalized cancer diagnostics supported by enhanced bioinformatics platforms.

The lung cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $1.12 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be attributed to increasing lung cancer incidence rates, limitations of tissue biopsy procedures, advancements in molecular diagnostics, availability of circulating biomarker technologies, growth of oncology research activities.

Download a free sample of the lung cancer liquid biopsy market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24593&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Industry Players in the Lung Cancer Liquid Biopsy Sector
Several prominent companies are at the forefront of the lung cancer liquid biopsy market. These include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., and Oncocyte Corporation. A notable recent development occurred in February 2024, when Veracyte Inc., a US-based molecular diagnostics firm, acquired C2i Genomics Inc. The acquisition aims to strengthen Veracyte's cancer diagnostic capabilities by incorporating advanced whole-genome MRD liquid biopsy technologies to enhance cancer detection and monitoring across various types, including lung cancer.

Advancements and Future Directions in the Lung Cancer Liquid Biopsy Market
Companies within this market are actively pursuing innovative technologies such as blood-based lung cancer screening tests. These non-invasive tests analyze biomarkers circulating in the blood to detect lung cancer at an early stage, improving diagnostic precision and enabling real-time monitoring of tumor progression and treatment response. For example, in October 2023, DELFI Diagnostics Inc., a biotechnology company based in the US, introduced FirstLook Lung. This blood-based liquid biopsy test utilizes fragmentomics to detect early-stage lung cancer with high sensitivity and a 99.8% negative predictive value. Its development aims to boost early detection rates, promote wider screening, and optimize subsequent imaging referrals for patients at risk.

View the full lung cancer liquid biopsy market report:
https://www.thebusinessresearchcompany.com/report/lung-cancer-liquid-biopsy-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Market Breakdown of the Lung Cancer Liquid Biopsy Industry by Type, Application, and Region
The lung cancer liquid biopsy market is segmented across multiple dimensions to provide a comprehensive analysis:
1) By Product: Instruments, Consumables/Kits/Reagents, Software and Services
2) By Technology: Multi-Gene Parallel Analysis (NGS), Single-Gene Analysis (PCR, Microarrays)
3) By Biomarker: Cell-Free DNA, Circulating Tumor DNA, Extracellular Vesicles, Circulating Tumor Cells, Other Biomarkers
4) By Clinical Application: Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Other Applications
5) By End User: Diagnostics and Imaging Centres, Hospitals, Academic and Research Institutions, Other End Users

Further subcategories include:
- Instruments such as PCR Instruments, Microarray Instruments, and Next-Generation Sequencing (NGS) Instruments
- Consumables, Kits, and Reagents including Sample Collection Kits, Amplification Reagents, and Sequencing Reagents
- Software and Services like Data Analysis Software, Cloud-Based Services, and Bioinformatics Tools

This detailed segmentation underscores the market's complexity and highlights the various technological and clinical components driving its growth worldwide.

What's included in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.